GSK1120212 vs chemotherapy in advanced or metastatic BRAF V600E/K mutation-positive melanoma
Trial overview
Progression-free survival in BRAF V600E mutation-positive participants without a history of brain metastases as assessed by the Investigator and Independent Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Progression-free survival in all participants
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS in BRAF V600E mutation-positive participants without a history of brain metastases and without prior chemotherapy as assessed by the Investigator
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
PFS in BRAF V600E mutation-positive participants without a history of brain metastases and with prior chemotherapy as assessed by the Investigator
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Overall Survival in all participants
Timeframe: Day 1 until death due to any cause (average of 20.3 months)
Overall Survival in BRAF V600E mutation-positive participants without a history of brain metastases
Timeframe: Day 1 until death due to any cause (average of 20.3 months)
Number of BRAF V600E mutation-positive participants without a history of brain metastases with Overall Response (OR) as assessed by the Investigator and Independent Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of participants with OR as assessed by the Investigator and Independent Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of BRAF V600E mutation-positive participants classified as confirmed responders (CR and PR) as assessed by the Investigator
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of BRAF V600K mutation-positive participants classified as confirmed responders (CR and PR) as assessed by the Investigator
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
Number of participants with OR following Cross-over to Trametinib
Timeframe: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
Duration of Response (DoR) for all BRAF V600E mutation-positive participants without a prior history of brain metastases classified as confirmed responders (CR or PR) as assessed by the Investigator Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for all BRAF V600E mutation-positive participants without a prior history of brain metastases classified as confirmed responders (CR or PR) as assessed by the Independent Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for all confirmed responders (CR or PR) as assessed by the Investigator Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for all confirmed responders (CR or PR) as assessed by the Independent Review
Timeframe: Day 1 until the earliest date of disease progression or death due to any cause (average of 20.3 months)
DoR for all responders (CR or PR) following cross-over to Trametinib as assessed by the Investigator
Timeframe: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
PFS following cross-over to Trametinib as assessed by the Investigator
Timeframe: Day 1 of cross-over therapy until the earliest date of disease progression or death due to any cause (average of 18.3 months)
Participation criteria
- ≥18 years of age
- Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
- Any prior use of BRAF inhibitors or MEK inhibitors.
- Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
- ≥18 years of age
- Stage III unresectable (Stage IIIc) or metastatic (Stage IV) cutaneous melanoma which is also determined to be BRAF V600E/K mutation-positive by the central laboratory
- Received no prior treatment or up to one prior regimen of chemotherapy for advanced or metastatic melanoma. Prior treatment with immunotherapy (with the exception of prior ipilimumab, which is only allowed if given in the adjuvant setting), cytokine therapy, biological or vaccine regimen is permitted. Prior use of sorafenib is allowed
- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- Women of childbearing potential and men with reproductive potential must agree to use effective contraception during the study. Additionally women of childbearing potential must have a negative serum pregnancy test within 14 days prior to randomization
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1
- Adequate screening organ function
- Any prior use of BRAF inhibitors or MEK inhibitors.
- Subjects who have received dacarbazine or paclitaxel prior to randomization will not be eligible to receive the same chemotherapy as study medication (i.e. a subject who received prior dacarbazine cannot receive dacarbazine on this trial and would thus receive paclitaxel if randomized to the control arm)
- History of another malignancy. Exception: Subjects who have been disease-free for 3 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible. Subjects with second malignancies that are indolent or definitively treated may be enrolled. Consult GSK Medical Monitor if unsure whether second malignancies meet requirements specified above
- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection which will be allowed)
- Brain metastases with the following exceptions that are ALL confirmed by the GSK Medical Monitor: All known lesions must be previously treated with surgery or stereotactic radiosurgery, and Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to randomization (must be documented with two consecutive MRI or CT scans using contrast), and asymptomatic with no corticosteroids requirement for ≥ 30 days prior to randomization, and no enzyme-inducing anticonvulsants for ≥ 30 days prior to randomization
- QTcB ≥ 480 msec. •History or evidence of current clinically significant uncontrolled arrhythmias. Exception: Subjects with controlled atrial fibrillation for >30 days prior to randomization are eligible •History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization. •History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association
- History of interstitial lung disease or pneumonitis
- Evidence of new optic disc cupping.
- Intraocular pressure > 21 mm Hg as measured by tonography
History or evidence of cardiovascular risk including any of the following:
History or current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy (CSR): •History of RVO or CSR, or predisposing factors to RVO or CSR (e.g. uncontrolled glaucoma or ocular hypertension, uncontrolled hypertension, uncontrolled diabetes mellitus, or history of hyperviscosity or hypercoagulability syndromes). •Visible retinal pathology as assessed by ophthalmic exam that is considered a risk factor for RVO or CSR such as:
Trial location(s)
Study documents
If you wish to request for full study report, please contact - [email protected]
Results overview
Results posted on ClinicalTrials.gov
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.